Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tarah J Ballinger

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Frontiers in Oncology|August 28, 2018
Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast CancerTarah J Ballinger, Jason B Meier, Valerie M Jansen
Breast Cancer Research : BCR|November 24, 2022
The bone-muscle connection in breast cancer: implications and therapeutic strategies to preserve musculoskeletal healthTarah J Ballinger, William R Thompson, Theresa A Guise
PEC Innovation|January 8, 2025
Improving communication to increase uptake of high-risk breast cancer prevention appointments: Building a better letterEvan K Perrault, Maria K Venetis, Tarah J Ballinger
Clinical Breast Cancer|December 18, 2014
Current HER2 Testing Recommendations and Clinical Relevance as a Predictor of Response to Targeted TherapyTarah J Ballinger, Melinda E Sanders, Vandana G Abramson
Seminars in Oncology|August 8, 2021
Landmark trials in the medical oncology management of metastatic breast cancerPei Lu, Cesar A Santa-Maria, Tarah J Ballinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2020
Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158Tarah J Ballinger, Guanglong Jiang, Nawal Kassem, et al.
European Journal of Haematology|September 27, 2014
How we manage JAK inhibition in allogeneic transplantation for myelofibrosisTarah J Ballinger, Bipin N Savani, Vikas Gupta, et al.
Cancer|July 22, 2014
Subtyping of triple-negative breast cancer: implications for therapyVandana G Abramson, Brian D Lehmann, Tarah J Ballinger, et al.
Clinical Advances in Hematology & Oncology : H&O|December 5, 2022
Energy balance in advanced breast cancer: extending beyond the curative settingTarah J Ballinger, Martha A Cancilla, Che Young Lee, et al.
NPJ Breast Cancer|October 8, 2024
Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancerTarah J Ballinger, Mary Lou Smith, Elda Railey, et al.
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Frontiers in Oncology|August 28, 2018
Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast CancerTarah J Ballinger, Jason B Meier, Valerie M Jansen
Breast Cancer Research : BCR|November 24, 2022
The bone-muscle connection in breast cancer: implications and therapeutic strategies to preserve musculoskeletal healthTarah J Ballinger, William R Thompson, Theresa A Guise
PEC Innovation|January 8, 2025
Improving communication to increase uptake of high-risk breast cancer prevention appointments: Building a better letterEvan K Perrault, Maria K Venetis, Tarah J Ballinger
Clinical Breast Cancer|December 18, 2014
Current HER2 Testing Recommendations and Clinical Relevance as a Predictor of Response to Targeted TherapyTarah J Ballinger, Melinda E Sanders, Vandana G Abramson
Seminars in Oncology|August 8, 2021
Landmark trials in the medical oncology management of metastatic breast cancerPei Lu, Cesar A Santa-Maria, Tarah J Ballinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2020
Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158Tarah J Ballinger, Guanglong Jiang, Nawal Kassem, et al.
European Journal of Haematology|September 27, 2014
How we manage JAK inhibition in allogeneic transplantation for myelofibrosisTarah J Ballinger, Bipin N Savani, Vikas Gupta, et al.
Cancer|July 22, 2014
Subtyping of triple-negative breast cancer: implications for therapyVandana G Abramson, Brian D Lehmann, Tarah J Ballinger, et al.
Clinical Advances in Hematology & Oncology : H&O|December 5, 2022
Energy balance in advanced breast cancer: extending beyond the curative settingTarah J Ballinger, Martha A Cancilla, Che Young Lee, et al.
NPJ Breast Cancer|October 8, 2024
Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancerTarah J Ballinger, Mary Lou Smith, Elda Railey, et al.
Pageof 5